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This study aims to compare the role of both subtraction MRI and Diffusion weighted
images in assessment of HCC after trans-arterial chemo embolization (TACE). Patients
and methods: 32 patients having 54 HCC lesions underwent TACE. Ages ranged between
59 and 73 years (mean age 59.6); there were 26 males and 6 females. All examinations
were performed using Philips 1.5 T MRI (Achieva). Pre contrast: T1, T2W and In phase
and out phase gradient echo sequence, dynamic: eTHRIVE technique performed.
Subtraction of an unenhanced T1-weighted was from the identical post enhancement
sequences in early angiographic and late arterial phases. Diffusion imaging: it was per-
formed using single-shot spin-echo echo-planar imaging with b = 0, 300, 600 mm/s2.
DWI was used to create ADC maps. Two readers blinded to each other assessed subtraction
of dynamic study and DWI technique to evaluate post treatment response. Results: Reader
1 subtraction dynamic MRI sensitivity = 97%, specificity = 100% PPV = 100% and NPV = 95%
compared to 70.59%, 75%, 82.76% and 60% respectively in DWI. Reader 2 subtraction
dynamic MRI sensitivity = 97%, specificity = 100% PPV = 100% and NPV = 95% compared to
76.5%, 90%, 92.8% and 69% respectively in DWI. Conclusion: DW-MRI had lower accuracy
measures compared to subtraction MRI with increased false negative. DWI may act as a
supplementary sequence to compensate for the dynamic MRI in patients who couldn’t hold
their breath adequately.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is considered to be the
fifth most common cancer worldwide [1]. Cirrhosis is
the major risk factor for development of hepatocellularcarcinoma, particularly cirrhosis due to chronic viral hep-
atitis and alcoholic cirrhosis [2].
Surgical resection is the prime curative treatment for
HCC management. Ablative techniques may be chemical
or thermal [3]. Chemical ablation guides the use of ethanol
and acetic acid, whereas thermal ablation is achieved by
using heat (radiofrequency ablation, laser ablation, or
microwave ablation) or cold (cryoablation) [3]. All these
therapeutic techniques result in tumor coagulative
necrosis [4].
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embolization of tumor vessels. The chemotherapeutic
agents reduce the tumoral blood flow. The embolizing par-
ticles prolong the contact of the tumor with the
chemotherapeutic agents. Lipiodol is used as a carrier for
the chemotherapeutic agents [4].
Complications and parenchymal changes following
TACE include the following: Post-embolization syndrome
(PES), Arterio-portal fistulae (APF), Parenchymal atrophy,
Portal vein obliteration, Bile duct injury and Acute
parenchymal infarct [5].
The assessment of the treatment efficacy is vital in
determining whether the chemoembolization has been
successful or not and thus aids in guiding future therapy,
and repeated negative biopsies do not exclude the pres-
ence of residual tumor. Thus monitoring treatment
response is important by radiological imaging to evaluate
any viable residual tumor [3].
Triphasic CT is the standard imaging technique to eval-
uate the therapeutic response. It is done immediately post
TACE to ensure the lipiodol retention by the tumor and
then repeated 1 month later to detect any tumoral residue
or recurrence [4].
On the other hand, MRI is more efficient than MDCT in
the detection of viable residual tumor elements following
TACE. Thus, the use of MRI is mandatory during the
follow-up [4].
Noncontrast T1 and T2 weighted images demonstrate
the morphological and fluid content changes as well as
fibrosis, while dynamic contrast enhancement (DCE) can
provide information on perfusion.
DCE-MRI is sensitive to vascular permeability and post
therapeutic changes in blood volume that can be associ-
ated with tumor angiogenesis [6].
Adequately treated tumors by TACE are usually
replaced by necrosis and reduced interstitial tissue fluid
because of the concomitant arterial occlusion.
On DCE-MRI post-TACE enhancement represents either
granulation tissue or residual tumoral tissue mixed with
necrotic regions. Differentiation is based on the phase of
enhancement. Granulation tissue shows delayed uptake
whereas residual tumoral tissue gives early arterial
enhancement denoting unsuccessful TACE treatment [6].
Evaluation of tumoral response by maximum size e.g.
RECIST or mRECIST was not accurate as some tumors show
paradoxical enlargement due to hemorrhage, edema or
necrosis. As a result further tools were utilized as func-
tional DWI-MRI or subtraction DCE-MRI [7].
Diffusion-weighted imaging (DWI) provides main infor-
mation about tumor cellularity and cell membrane integ-
rity. So, it may be sensitive to the changes that occur in
the tumor microenvironment following treatment [8]. It
also can be evaluated quantitatively by calculation of the
apparent diffusion coefficient (ADC). ADC has the potential
to predict the tumor response to treatment weeks before
the morphological changes appear [6]. DWI increased the
sensitivity for the detection of post TACE residual HCC.
However hypercellularity intermingled with a fibrotic con-
tent in the inflammatory granulation tissue could causerestricted diffusion, resulting in sustained hyperintensity
on DWI [9].
Subtraction imaging is a technique where a non-
enhanced T1-weighted sequence is digitally subtracted
from the T1-weighted image achieved after gadolinium
administration. Thus the subtraction imaging is helpful
for the assessment of the therapeutic efficacy for post TACE
HCCs, which makes the detection of tumor enhancement
difficult on post-contrast T1-weighted images. By accom-
plishing this operation, any native T1 signal is removed
and the remaining signal on the subtracted images is only
due to enhancement [10].
The aim of this work was to assess HCC cases after
trans-arterial chemoembolization by both subtraction
dynamic contrast enhanced MRI and diffusion weighted
imaging to detect which is more accurate in detecting
residual tumor and assess the need for further treatment.
2. Patients and methods
Our study was a retrospective study included 32
patients having 54 HCC lesions who underwent TACE pro-
cedure over a period of 12 months (January 2015–Decem-
ber 2015). All patients underwent TACE and 11 of them
underwent a follow-up within 1 month by triphasic CT or
dynamic MRI.
The patients’ ages ranged between 59 and 73 years
(mean age 59.6); there were 26 male patients and 6 female
patients. All patients had liver cirrhosis related to chronic
viral hepatitis.
All cases had been subjected to the following:
 Full clinical assessment.
 Checking the patient’s laboratory investigations includ-
ing renal function tests (urea and creatinine).
 Checking the previous radiological investigations done
for the patient.
 The study was approved by the ethics committee of our
institution and written consent was taken from all
patients.
Patients were scheduled to undergo MRI within
1 month after embolization and were advised for further
follow-up 3 months later.
Exclusion criteria:
1. Contraindications to contrast media, e.g. patients with
renal failure, patients allergic to contrast media.
2. Contraindications to magnetic resonance imaging, e.g.
claustrophobia in patients contraindicated for anesthe-
sia, non-MR compatible cardiac prosthesis, pacemakers,
metallic plates.
3. Liver tumors other than hepatocellular carcinoma.
4. Procedures other than TACE e.g. RF, microwave
ablation.
MRI protocol:
All cases were performed using 1.5 T MRI scanner
(Achieva, Philips Healthcare, Eindhoven, The Netherlands).
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We start by manual bolus injection of 0.1 mmol/kg
body weight of Gd-DTPA from the antecubital vein and
flushed with 20 ml of sterile saline solution.
Dynamic imaging was carried out using 3D fat-
suppressed T1-weighted gradient echo sequence (THRIVE
i.e. T1 high resolution isotropic volume examination). A
dynamic series consisted of one pre contrast series and
then three successive post contrast series including early
arterial, late arterial, and portal phases with 19–21 s
intervals (17 s for image acquisition with breath-holding
and 2–4 s for re-breathing).
This is followed by delayed phase imaging at 5-min. All
patients were imaged in end expiration to limit the risk of
image misregistration.
(b) Diffusion weighted images:
Functional DWI was performed using single-shot spin-
echo-planar imaging during one or more breath holds.
ADC parametric maps were reconstructed from each set
of DW images acquired at each slice position.
Analysis of the MR images:
Images were sent to the workstation (Phillips Extended
MR Workspace) for further image processing.
 Subtraction imaging was then performed which is an
automated process available on the workstation, in
early and late arterial phases.
 By this process, any native T1 signal is removed and the
remaining signal on the subtracted images is solely due
to enhancement.
DWI was used to create ADC maps and subsequently
ADC values were measured and recorded.
 The morphological criteria of each lesion were recorded
including the number of treated lesions, site, size, mar-
gins and signal intensity at T1, T2 and SPAIR images.
 Assessment for the presence of complications, residual
or recurrent tumor viability.
Dynamic study analysis:
We perform early and late arterial, portal and delayed
phases after the single pre-contrast series.
Pattern of enhancement (through the successive
dynamic series) was then studied.
Subtraction dynamic study analysis:
Pattern of enhancement in the Subtraction dynamic
imaging was then studied.
 DWI:
– Qualitative assessment for restricted and facilitated
areas of the treated lesions, where lesions were
with high signal or low signal was correlated with
ADC maps to exclude T2 shine through effect or T2
blackout.
– ADC maps were assessed both qualitatively by
recording the signal intensity and quantitatively by
measuring ADC values in the areas of restriction thatshowed pathological enhancement in the late arte-
rial images.
ADC measurement:
 ADC maps are pixel-based that were generated on the
workstation. ADC was estimated with linear regression
analysis of the function S = S0  exp (–b  ADC), where
S is the signal intensity after application of the diffusion
gradient, and S0 is the signal intensity at a b value of
0 s/mm2. Three b values (0, 300, and 600 s/mm2) were
used for ADC calculation.
 Areas of hyper-intensity on DWI were correlated with
T2 WI to exclude the presence of T2 shine through or
blackout effects.
 The restricted areas were correlated with THRIVE
images to confirm the presence of enhancement.
 A circular region of interest (ROI) was drawn around the
suspected lesions either through contrast enhancement
due to residual/recurrent disease or due to reactive
enhancement or intra-lesional restriction.
 If no high signal or enhancement could be identified,
the whole lesion was measured.
Interpretation of the MR image:
MR images were interpreted by two readers who are
experienced in hepatic imaging. Each reader interpreted
the Dynamic MRI and subtraction MRI images and com-
pared it to the findings of diffusion weighted images and
ADC value was recorded.
Signal of the embolized zone at T1, T2 and SPAIR WIs
was classified as high, low or heterogeneous.
A. Dynamic study interpretation:
 Recorded arterial phase enhancement and delayed
washout were suggestive of residual tumoral
activity.
 The absence of enhancement in the arterial phase
was suggestive of proper tumor embolization.
B. Subtraction dynamic studies:
Findings were confirmed/excluded by the subtrac-
tion images to prove that in the arterial phase the
increased signal is due to enhancement and not due to
the original pre-contrast high T1 signal of the coagulative
necrosis.
Intense enhancement at the margin of the embolization
zone which may be either:
 Granulation tissue rim: Persistent or delayed phase
enhancement.
 Nodular, hallow or gross enhancement: that suggest
tumor recurrence.
We categorize the patients into two groups:
 Resolved group (Well ablated): no MRI signs of residual
or recurrent viability (regardless of the presence of
newly developed lesions) by both readers.
 Unresolved group (residual): evidence of residual or
recurrent tumor by both readers.
Table 1
The general evaluation of the cases according to mRECIST and EASL criteria by both readers In 1ry response and follow-up findings post TACE.
Reader 1 Reader 2
Count % Count %
Response Good response 20 37.0 18 33.3
RESIDUE 34 63.0 36 66.7
No response 0 .0 0 .0
Follow-up Regression 8 47.1 8 47.1
Progressive 2 11.8 1 5.9
Stationary 7 41.2 8 47.1
Table 2
Correlation of DWI to THRIVE noting the efficiency of DWI in detecting residual disease post TACE by both reader 1 and reader 2.
THRIVE (dynamic) (reader 1)
Enhancing residue Non-enhancing/enhancing
reactive
Count % Count %
DWI (reader 1) RESTRICTED (+ve) 24 70.6 5 25
FACILITATED (ve) 10 29.4 15 75
THRIVE (dynamic) (reader 2)
Enhancing residue Non-enhancing/enhancing
reactive
Count % Count %
DWI (reader 2) RESTRICTED (+ve) 26 76.5 2 10.0
FACILITATED (ve) 8 23.5 18 90.0
Table 3
Correlation of subtraction to THRIVE noting the efficiency of subtraction in detecting residual disease post TACE by both reader 1 and reader 2.
THRIVE (dynamic) (reader 1)
Enhancing residue Non-enhancing/
enhancing reactive
Count % Count %
Subtraction (reader 1) Enhancing residue 33 97.1 0 0
Non-enhancing/enhancing reactive 1 2.9 20 100.0
THRIVE (dynamic) (reader 2)
Enhancing residue Non-enhancing/
enhancing reactive
Count % Count %
Subtraction (reader 2) Enhancing residue 33 97.1 0 0
Non-enhancing/enhancing reactive 1 2.9 20 100.0
Table 4
Correlation of data obtained from both readers including all results of DWI, subtracted dynamic image, and THRIVE.
Reader 1 Reader 2
Count % Count %
DWI FACILITATED (ve) 25 46.3 26 48.1
RESTRICTED (+ve) 29 53.7 28 51.9
Subtraction Nonenhancing/enhancing reactive 21 38.9 21 38.9
Enhancing residue 33 61.1 33 61.1
THRIVE (dynamic) Nonenhancing/enhancing reactive 20 37.0 20 37.0
Enhancing residue 34 63.0 34 63.0
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Data were recorded and entered using the statistical
package SPSS (Statistical Package for the Social Science;
SPSS Inc., Chicago, IL, USA) version 22. Data were displayed
using mean, median, standard deviation, minimum and
maximum in quantitative data and using frequency
(count) and relative frequency (percentage) for categorical
data. Standard diagnostic indices including sensitivity,
specificity, positive predictive value (PPV), negative predic-
tive value (NPV) and diagnostic efficacy were estimated.
ROC curve was constructed with area under curve analysis
performed to detect best cutoff value of ADC for detection
of residue. For comparing categorical data, Chi square (v2)
test was performed. Exact test was used instead when the
expected frequency is less than 5. Agreement between the
2 readers was done using Kappa measure of agreement.
3. Results
This was a retrospective study included 32 patients
with 54 HCC lesions with ages ranging from 59 to 73 with
the mean of age of 59.6 years. Of the 32 patients only 6
(18.75%) were females and 26 (81.25%) were males. Out
of the 32 cases only 12 cases came back for follow-up afterTable 5
Sensitivity, specificity, PPV, NPV of both DWI and subtraction as viewed by
both readers.
Reader 1 Reader 2
Diffusion WIs
Sensitivity 70.6% 76.5%
Specificity 75% 90%
PPV 82.7% 92.8%
NPV 60% 69%
Subtraction
Sensitivity 97% 97%
Specificity 100% 100%
PPV 100% 100%
NPV 95% 95%
Fig. 1. Both readers noticed subtraction results to have g3 months interval displaying 17 treated lesions on follow-
up by contrast enhanced MRI.
Table 1 represents the general evaluation of the cases
according to mRECIST and EASL criteria by both readers
In 1ry response and follow-up findings post TACE. Where
good response was defined as disappearance of any intra
tumoral arterial enhancement in treated lesions, residual
disease was defined as at least 30% reduction in the sum
of diameters of the viable enhancing lesion in the arterial
phase. No response was less than 30% reduction in the
enhancing lesion diameters. Progressive disease was
defined as 20% increase in the sum of diameters of the
enhancing lesions in comparison with the target lesion
diameter at the start of treatment.
Table 1 shows that residual disease was detected in 63%
and 66% of the lesions by reader 1 and reader 2 respec-
tively. On the other hand 37% and 33.3% of the cases
showed a good therapeutic response respectively. Both
readers agreed that none of the cases showed no response
to treatment. On follow-up for [17] of those lesions regres-
sion was confirmed in 47.1% of the lesions by both readers,
while progressive course was detected in 11.8% by reader 1
and 5.9% by reader 2 respectively. A stationary course was
observed in 41.2% and 47.1% by reader 1 and reader 2
respectively.
The P value was <0.001 denoting significant agreement
between both readers.
Table 2 illustrates how facilitated lesions on DWI repre-
sent good therapeutic response of 75% of non-enhancing
lesions, while around 30% of the facilitated lesions were
enhancing (i.e. false negative). On the other hand 70% of
the restricted lesions were enhancing on THRIVE with only
5% being restricted and non-enhancing (i.e. false positive)
(reader 1).
Considering reader 2, facilitated lesions represent good
therapeutic response in up to 90% of non-enhancing
lesions, while around 23% of the facilitated lesions were
enhancing (i.e. false negative). On the other hand 76% of
the restricted lesions were enhancing on THRIVE with onlyreater agreement with THRIVE than those of DWI.
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positive).
False negative results were attributed to 1ry high ADC
value of well differentiated HCC, so these lesions still
showed enhancement due to partial response to TACE
while they were falsely facilitated on DWI.
False positive results were attributed to lipiodol deposi-
tion in the tumor giving no enhancement but only false
restriction on DWI.Fig. 2. ROC curve for detection of residue
Fig. 3. ROC curve for detection of residueTable 3 illustrates how the absence of enhancement
represents good therapeutic response in 100% of lesions
in both THRIVE and subtraction, while enhancement repre-
sents residue in almost 97% of the lesions in both studies.
False negative results were obtained in 0% of the lesions
by subtraction and only 2.9% false positive as recorded by
both readers.
Table 4 interprets the results for each reader obtained
from all three sequences in the form of facilitated versusSource of the Curve
___ subtraction (reader 1)
___ ADC (reader 1)
by ADC and subtraction (reader 1).
Source of the Curve
___ subtraction (reader 2)
___ ADC (reader 2)
by ADC and subtraction (reader 2).
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tion and THRIVE. Furthermore all results were expressed
as a percentage from the total number of lesions. Although
both readers agreed that 34 lesions had residual disease by
conventional dynamic MRI, subtraction was able to deduct
the number to 33 enhancing lesions by removing native T1
signal from enhanced images. It also increased the
conspicuity of the embolized lesions for both readers
achieving a higher confidence level.
In spite of under estimating the disease burden in 5
cases by reader 1 and 6 cases by reader 2, DWI is stillFig. 4. Case (1): 64 years old male patient having HCC underwent TACE ablation
high peri-lesional signal in the smaller one, and intralesional high signal in the
intralesional signals in both lesions not differentiating enhancement from necr
denoting intralesional hemorrhage and peripheral reactive hyperaemia, but no re
(red arrow) and the smaller one can’t be seen on DWIs. (e) ADC map shows m
segment IVa lesion (red arrow) with high perilesional signal and low central
nodularity. (h) Late subtracted images made the peripheral nodular enhancemen
of high signal confirming with restriction on ADC map consistent with residualpresented as a useful confirmative tool with other diagnos-
tic series in 53.7% and 52% of lesions by reader 1 and reader
2 respectively.
According to Table 5 reader 1 subtraction dynamic MRI
had a sensitivity of 97.06%, a specificity of 100%, a positive
predictive value of 100% and a negative predictive value of
95%, compared to 70.59%, 75%, 82.76% and 60% respec-
tively in diffusion weighted imaging.
According to Table 5 reader 2 subtraction dynamic MRI
had a sensitivity of 97.06%, a specificity of 100%, a positive
predictive value of 100% and a negative predictive value offor 3 focal lesions. (a) T1WI shows two focal lesions in segment VIII with
larger one (arrows). (b) Late arterial phase image shows high peri and
osis. (c) Subtracted late arterial shows low intra and peri lesional signal
sidual disease in both lesions. (d) The larger lesion could be demonstrated
ean ADC value was 1.1  103 mm2/s for larger lesion. (f) T1WI shows a
signal. (g) Late arterial image shows thick marginal enhancement with
t more conspicuous denoting residual malignancy. (i) DWI shows an area
disease. (j) ADC value of 1.14  103 mm2/s.
Fig. 4 (continued)
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diffusion weighted imaging.
In subtraction the AUC (95% CI) was 0.985 with range of
(0.95–1.019) producing a significant P-value of <0.001.
However in ADC the AUC (95% CI) wasn’t as significant,
ranging from 0.3 to 0.63 producing an insignificant P-value
of 0.64.
In subtraction the AUC (95% CI) was 0.906 with range of
(0.811–1.001) producing a significant P-value of <0.001.
However in ADC the AUC (95% CI) wasn’t as significant,
ranging from 0.398 to 0.84 producing an insignificant P-
value of 0.563.Our failure to generate a cutoff value for malignant
lesions may be attributed to the small scale of our study.
Furthermore it was detected that ADC values may vary
according to the 1ry tumoral histological grade giving high
ADC values for well differentiated HCC and vice versa.4. Discussion
Trans-arterial chemoembolization (TACE) is currently
recommended as first-line palliative therapy of Hepatocel-
lular carcinoma (HCC) for non-surgical patients [11].
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ablated treatment zones (TZs). MRI enhancement charac-
teristics are indicator for treatment efficacy and may sug-
gest the need for further intervention. Reduction in tumor
size is a validated parameter used to assess treatment
response [Response Evaluation Criteria in Solid Tumors
(RECIST)]; however, this does not take into account that
non-viable HCC may show no reduction in size in the early
post-treatment period [12]. The American Association for
the Study of Liver Disease (AASLD) and the European Asso-
ciation for the Study of the Liver (EASL) proposed the tumor
enhancement a biomarker of disease response [12].Fig. 5. Case (2): 63 years old male patient with one large HCC lesion in subcapsula
of TACE ablation. (a) T1WIs shows high intralesional signal denoting post emboli
showing the high intralesional signal but with indistinct margins of the lesion. I
image shows that subtraction removes the intralesional high signal and no fur
margins of the lesion remain indistinct. (e) DWI b-value 600 shows distinct lesion
denotes restriction versus T2 shine through. (f) Mean ADC value of the whole lesi
(1.7  103 mm2/s) and peripheral mean ADC (1.6  103 mm2/s).Conventional gadolinium-enhanced MRI might not dif-
ferentiate therapy-induced inflammation and granulation
tissue from viable tumor [13]. Due to these limitations,
alternative MRI techniques are required to reflect tumor
response accurately [14] (see Figs 1–3).
Coagulative hemorrhagic necrosis results in high signal
on the unenhanced T1-weighted images in the TZs. Sub-
traction MRI is a technique in which unenhanced and
contrast-enhanced T1-weighted sequences are digitally
subtracted using MRI software in order to remove pre-
existing T1-weighted high signal from the post-processed
images so that the remaining high signal is only due tor position in segment VII came for follow-up 1 month post his first session
zation hemorrhage within the lesion. (b) Early arterial, (c) late arterial still
ntra lesional enhancement can’t be ruled out. (d) Subtracted late arterial
ther enhancement can be detected, i.e. no residue or recurrence. But the
margins with low signal denoting facilitation. And the high internal signal
on shows over all facilitation of the lesion with over all mean ADC value of
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in our cases 1, 2 and 3 (Figs. 4c and h, 5d and 6d).
Diffusion-weighted imaging (DWI), detects early MR
signal changes in tissues according to the degree of cell
membrane integrity [8]. Necrotic tumor cells with dis-
rupted cell membranes exhibit increased water diffusion.
The apparent diffusion coefficient (ADC) is used to quantifyFig. 6. Case (3): 69 years old male patient with large HCC lesion at segments VI
4 months later. First follow-up was by dynamic MRI, and the second correlation
show that white arrow indicates areas of low signal intensity of liquefactive
Subtracted late arterial image shows regular enhancing rim (red arrow) with
confirming good therapeutic response. (e) DWI b value 600 qualitative asses
correspond to quantitative restriction with mean ADC value of 0.4–0.5  103 m
stagnation of the lipiodol droplets corresponding to areas of ADC restriction. Alsthe mobility of water. Therefore tumor necrosis is
associated with an increase in ADC value, thereby allowing
differentiation between viable and necrotic portions of
tumor [16].
The measurements of ADC values are always subjected
to some intra and inter observer variabilities [18]. We were
not able to calculate an ADC cutoff value from the ROCand VII underwent one session of TACE, and came for follow-up 1.5 and
was by triphasic CT. (a)–(c) T1WI, early arterial and late arterial images
necrosis and red arrow indicates areas of high signal likely residue. (d)
internal septations of the lesion denoting lack of residual disease and
sment shows areas of marked peripheral restriction marginally which
m2/s (red arrow). Further serial non-contrast CT images (f) show marginal
o further follow-up for this case confirmed good therapeutic response.
Fig. 7. Case (4): 68 years old male patient with large HCC lesion located at in segment VII and VIII underwent TACE, and came for follow-up 6 weeks later.
(a) Subtraction image shows persistent peripheral nodular enhancement. (b) and (c) DWIs and ADC map show diffuse qualitative restriction with mean ADC
values varying between 1.0 and 1.1  103 mm2/s. (d) Portal venous phase shows lack in parenchymal enhancement in a wedge shaped area (white arrow)
with total lack of contrast. In the right posterior portal vein (red arrow) compared to the left portal vein (green arrow) denoting parenchymal infarction. (e)
DWIs show facilitation at this area with an ADC value measuring (1.8–1.9  103 mm2).
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negative identification of necrotic tissue may result from
well-differentiated HCC. Similar to what was found by
[19], the viable tumor tissues and necrosis may sometimes
be difficult to differentiate according to the visual assess-
ment of the DWMRI alone.
Causes of false negative results of DWI may be due to
increased ADC of tumor in well differentiated HCC or
whether circular region of interest (ROI) used for ADCFig. 8. Case (5): 53 year old male patient with treated HCC by TACE in segments V
phase shows portal vein branch directly connected to the right portal branch (r
shaped area with minimal capsular bulge. (c) DWI shows hyperintense signal we
in ADC (d) related to A-P fistula with mean ADC value of 0.7–0.8  103 mm2/s.calculation may wrongly include areas of nearby necrotic
tissue. Included peritoneal fat may also raise the ADC
values. False negative results of DWI are also when small
subcentimetric lesions aren’t clearly seen [18], as
presented in case 1 (Fig. 4).
Causes of false positive results of DWI may be attribu-
ted to hemorrhage and coagulative necrosis that may fal-
sely lower ADC values and also intralesional lipiodol
accumulation may lead to intralesional restriction [19].I and VII and came for his first follow-up one month later. (a) Early arterial
ed arrow). (b) Subtracted late arterial phase shows hyper intense wedge
dge shaped area corresponding to area of relative parenchymal restriction
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accumulation gives false restriction and thus leaving sub-
traction superior in such case (case 3, Fig. 6).
In our study, the mean ADC value for necrotic lesions
was 1.16 and 1.24 as detected by reader 1 and reader 2
respectively. The mean ADC for residual disease was 1.07
and 1.05 as detected by both readers respectively.
Reader 1 evaluation yielded a sensitivity of 70.59%, a
specificity of 75%, a positive predictive value of 82% and a
negative predictive value of 60%, compared to 76.47%,
90%, 92.86% and 69.23% respectively in reader 2 with a
confidence interval of 64–94% for reader 1 and 76–99%
for reader 2.
Our results were different from those elicited by
Goshima et al. [20], who observed that diffusion weighted
imaging had a 100% sensitivity, a 65.5% specificity, a posi-
tive predictive value of 67.7%, a negative predictive value
of 100% and an overall agreement of 80%.
Refs. [16,19] reported that DWI and ADC values quan-
tify tumor necrosis following chemoembolization much
more than gadolinium-enhanced MRI. However, our
results agreed with [17] who showed that contrast-
enhanced MRI with subtraction technique revealed a sig-
nificant correlation with the histopathological findings
more than DWI, in the evaluation of necrosis in HCC fol-
lowing TACE. In addition, [21] stated that DWI was not a
reliable predictor of local HCC recurrence following TACE
compared to gadolinium-enhanced MRI.
However, the degree of tumor necrosis of large HCC fol-
lowing TACE may be predicted by DWI [19].
This is in agreement with our study and presented in
cases 2 and 3 (Figs. 5 and 6).
Image subtraction:
In our study we noted that both readers had the same
statistical values as noted: sensitivity 97.06% specificity
100%, positive predictive value 100%, NPV 95.24%. Conse-
quently both readers agreed to a PPV of 100% with CI
95% = 89–100%, NPV of 95% with CI 95% = 76–99%. Our
results correlated with [22] who reported a sensitivity of
92%, specificity of 100%, and accuracy of 93% for the detec-
tion of viable tumor after TACE (in 30 HCCs) using double-
contrast MRI [superparamagnetic iron oxide (SPIO) and
Gd-DTPA agents].
Subtraction gained higher sensitivity and specificity
and confidence interval by
 Providing specific contrast enhancement patterns.
 Peripheral nodular enhancement for residual disease.
 Rim contrast enhancement for reactive perilesional
hyperaemia.
 No enhancement for well ablated lesions [23].
These findings are similar to what were presented in
our cases (1–3) Figs. 4–6.
Small sized tumors were challenging but many of the
lesions ranged in size from 0.8 to 1.5 cm were clearly
detected on subtraction but not seen on DWI (case 1,
Fig. 4).
However [23–25] excluded all lesions below 1 cm in
size from their studies in fear that they may be vulnerable
to image misregistration.Motion artifacts weren’t having that great effect on the
diagnostic series especially in cases with minimal misreg-
istration artifacts, and the confidence interval was still
high. This was consistent to [25] in their study; there were
eight cases of minimal misregistration.
Complications and parenchymal changes following
TACE were described by [5] and in our study we found that
subtraction specifies complications and their site, where
DWI may be as sensitive but non-specific (cases 4 and 5,
Figs. 7 and 8).
Limitations of our study are that it was a retrospective
study so it is prone to the limitations inherent to all studies
of this design. The sample size was small due to the strict
selection criteria adopted for this highly specialized indica-
tion. This reduced the power of the statistical analysis. The
Standard of reference SOR was not based on histology. No
biopsies were performed to confirm complete treatment
necrosis or residual disease, due to ethical and practical
difficulties in performing TZ biopsies in all cases.
Finally we conclude that, MRI is a powerful tool in
detection of tumor viability and complications after TACE.
Imaging protocol should include dynamic study combined
with post processing subtraction images for better tissue
characterization. DWI can be used for patients who can’t
receive GD-DTPA and to quantify tumor necrosis in large
HCC. Compared to DWI, Subtraction MRI is much more
valuable, where it increases radiologists’ confidence in
interpreting treatment response following loco-regional
therapies for HCC.Conflict of interest
The authors declared that there is no conflict of interest.
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